logo
First-of-its-kind brain computer helps man with ALS speak in real-time

First-of-its-kind brain computer helps man with ALS speak in real-time

India Today12-06-2025
In what could be one of the bioggest breakthrough in medical science and technology a newly developed investigational brain-computer interface could restore voice of people who have lost the ability.The team from University of California, Davis succesfully demonstrated this new technology, which can instantaneously translate brain activity into voice as a person tries to speak. The technology promises to create an artificial vocal tract.advertisementThe details, published in journal Nature, highlight how the study participant, who has amyotrophic lateral sclerosis (ALS), spoke through a computer with his family in real time. The technology changed his intonation and 'sang' simple melodies.
'Translating neural activity into text, which is how our previous speech brain-computer interface works, is akin to text messaging. It's a big improvement compared to standard assistive technologies, but it still leads to delayed conversation. By comparison, this new real-time voice synthesis is more like a voice call,' said Sergey Stavisky, senior author of the paper.The investigational brain-computer interface (BCI) was used during the BrainGate2 clinical trial at UC Davis Health. It consists of four microelectrode arrays surgically implanted into the region of the brain responsible for producing speech.
The researchers collected data while the participant was asked to try to speak sentences shown to him on a computer screen. (Photo: UCD)
advertisement'The main barrier to synthesizing voice in real-time was not knowing exactly when and how the person with speech loss is trying to speak. Our algorithms map neural activity to intended sounds at each moment of time. This makes it possible to synthesize nuances in speech and give the participant control over the cadence of his BCI-voice,' Maitreyee Wairagkar, first author of the study added.The system translated the participant's neural signals into audible speech played through a speaker very quickly — one-fortieth of a second.Researchers attributed the short delay to the same delay as a person experiences when they speak and hear the sound of their own voice.The technology also allowed the participant to say new words (words not already known to the system) and to make interjections. He was able to modulate the intonation of his generated computer voice to ask a question or emphasize specific words in a sentence.The process of instantaneously translating brain activity into synthesized speech is helped by advanced artificial intelligence algorithms.The researchers note that "although the findings are promising, brain-to-voice neuroprostheses remain in an early phase. A key limitation is that the research was performed with a single participant with ALS. It will be crucial to replicate these results with more participants."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Telescopes spot start of planet formation in Orion
Telescopes spot start of planet formation in Orion

The Hindu

time6 hours ago

  • The Hindu

Telescopes spot start of planet formation in Orion

When rocky worlds like the earth began to form, dust in the young Solar System was first heated until it vaporised and then cooled so that the very first, refractory (i.e. heat-loving) minerals could crystallise. Catching that moment in another star system would show astronomers exactly how planet formation begins — but no one had seen it before. A new study in Nature this month has reported just such an event. By examining the star HOPS‑315 in Orion, whose protoplanetary disc is tilted just enough for someone on or near the earth to peer deeper within, researchers from France, the Netherlands, Sweden, Taiwan, and the US observed raw rock vapour cool and crystallise. The protoplanetary disc is a flat, rotating pancake-shaped mass of gas and dust that surrounds a newborn star. Inside it, dust grains bump together, stick, and gradually grow into rocks, planets, moons, and other bodies while the gas creates atmospheres and influences the planets' long-term orbits. The observations themselves were conducted by the NASA James Webb Space Telescope and the Atacama Large Millimeter/sub‑millimeter Array (ALMA) observatory in Chile. In 2023, the team used the NIRSpec and MIRI integral‑field spectrographs onboard the telescope to collect sharp energy readings across a range of frequencies. Eight months later, ALMA observed the same system for signs of carbon monoxide, silicon monoxide and sulphur monoxide. Together, the telescope traced warm gas and dust only a few stellar radii from the star while ALMA mapped cooler gas farther out. The telescope's data contained evidence of a strong band of silicon monoxide gas at around 470 K as well as crystalline silicates. Both lay within 2.2 AU of the star — well inside Mercury's orbit if this were in the solar system. (1 AU equals the earth-sun distance.) The team also ran computer simulations, which predicted that around 1 AU from the star, temperatures hovered around 1,300 K, which is the temperature at which dust just begins to evaporate. The study's energy readings matched the prediction: that interstellar grains must have vaporised there, releasing silicon monoxide gas that then cooled and re-condensed into fresh shards of crystals. According to the study, the relative quantities of crystals of forsterite, enstatite, and tentative silica were reminiscent of inclusions — i.e. minerals trapped inside minerals — that have been found in primitive meteorites on the earth, meaning that a similar condensation chemistry is under way around the star. The ALMA data also revealed no slow silicon monoxide at the star's position whereas the Webb telescope's data was blueshifted by around 10 km/s. Together, they indicate that the minerals lay inside the rising disc atmosphere, the thin upper layer of gas and dust above the mid‑plane of the protoplanetary disc, rather than in the material pouring out of the star. Thus the study has reported the first evidence of solid matter condensing out of rock vapour around a star, a.k.a. the first step of planet formation.

Alzheimer: Researchers find two cancer drugs reverse damaged gene behaviour in mice
Alzheimer: Researchers find two cancer drugs reverse damaged gene behaviour in mice

Time of India

time9 hours ago

  • Time of India

Alzheimer: Researchers find two cancer drugs reverse damaged gene behaviour in mice

New Delhi: A study that compared gene behaviour in Alzheimer's disease with that caused by 1,300 drugs approved for use in the US has found that a combination of two cancer drugs could slow the neurodegenerative disease in mice, indicating a promise in reversing symptoms in humans. Alzheimer's disease is an ageing-related disorder in which cognitive function steadily declines, affecting speech and memory, and eventually can interfere with everyday activities. Scientists at the University of California, San Francisco, and Gladstone Institutes in the US first saw how gene behaviour was affected in Alzheimer's disease in a single brain cell. The researchers then looked at 1,300 drugs approved by the US Food and Drug Administration (FDA) and which of them reversed the damage. The next stage of the study, published in the journal 'Cell', analysed electronic medical records of about 1.4 million patients and found that patients who took some of these drugs for treating conditions other than Alzheimer's disease were less likely to get the ageing-related neurological disorder. Testing the top two drug candidates -- ' letrozole ' and ' irinotecan ', both of which are cancer medications -- in a mouse model having Alzheimer's disease, the researchers found that brain degeneration was reduced and a restored ability to remember. Letrozole is usually prescribed for treating breast cancer, and irinotecan for colon and lung cancer. The combined effects of two drugs were found to reverse damaged gene behaviour in neurons and glia (a type of brain cells that surround and support neurons). Further, toxic clumps of proteins and brain degeneration -- hallmark features of Alzheimer's -- were found to be reduced and memory restored, the researchers said. The team added that out of 1,300 drugs, 86 reversed gene behaviour changes in one type of brain cell and 25 reversed them in other types. However, only 10 had been approved for use in humans by the FDA. "Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five," said lead author Yaqiao Li, a postdoctoral scholar at Gladstone Institutes. "Alzheimer's disease comes with complex changes to the brain which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," said co-senior author Marina Sirota, professor of paediatrics and an interim director at the University of California. Co-senior author Yadong Huang, director of the center for translational advancement at Gladstone Institutes, said, "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health." "This makes it very challenging for drug development -- which traditionally produces one drug for a single gene or protein that drives disease," Huang said. The electronic medical records analysed in the study came from the University of California's Health Data Warehouse, which includes anonymised health information on 1.4 million people over the age of 65.

Alzheimer's disease: Researchers find two cancer drugs reverse damaged gene behaviour in mice
Alzheimer's disease: Researchers find two cancer drugs reverse damaged gene behaviour in mice

The Hindu

timea day ago

  • The Hindu

Alzheimer's disease: Researchers find two cancer drugs reverse damaged gene behaviour in mice

A study that compared gene behaviour in Alzheimer's disease with that caused by 1,300 drugs approved for use in the US has found that a combination of two cancer drugs could slow the neurodegenerative disease in mice, indicating a promise in reversing symptoms in humans. Alzheimer's disease is an ageing-related disorder in which cognitive function steadily declines, affecting speech and memory, and eventually can interfere with everyday activities. Scientists at the University of California, San Francisco, and Gladstone Institutes in the US first saw how gene behaviour was affected in Alzheimer's disease in a single brain cell. The researchers then looked at 1,300 drugs approved by the US Food and Drug Administration (FDA) and which of them reversed the damage. The next stage of the study, published in the journal 'Cell', analysed electronic medical records of about 1.4 million patients and found that patients who took some of these drugs for treating conditions other than Alzheimer's disease were less likely to get the ageing-related neurological disorder. Testing the top two drug candidates -- 'letrozole' and 'irinotecan', both of which are cancer medications -- in a mouse model having Alzheimer's disease, the researchers found that brain degeneration was reduced and a restored ability to remember. Letrozole is usually prescribed for treating breast cancer, and irinotecan for colon and lung cancer. The combined effects of two drugs were found to reverse damaged gene behaviour in neurons and glia (a type of brain cells that surround and support neurons). Further, toxic clumps of proteins and brain degeneration -- hallmark features of Alzheimer's -- were found to be reduced and memory restored, the researchers said. The team added that out of 1,300 drugs, 86 reversed gene behaviour changes in one type of brain cell and 25 reversed them in other types. However, only 10 had been approved for use in humans by the FDA. "Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five," said lead author Yaqiao Li, a postdoctoral scholar at Gladstone Institutes. "Alzheimer's disease comes with complex changes to the brain which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," said co-senior author Marina Sirota, professor of paediatrics and an interim director at the University of California. Co-senior author Yadong Huang, director of the center for translational advancement at Gladstone Institutes, said, "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health." "This makes it very challenging for drug development -- which traditionally produces one drug for a single gene or protein that drives disease," Huang said. The electronic medical records analysed in the study came from the University of California's Health Data Warehouse, which includes anonymised health information on 1.4 million people over the age of 65.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store